RecruitingPhase 2NCT07121413

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis

Studying Idiopathic pulmonary fibrosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Shanghai Synvida Biotechnology Co.,Ltd.
Intervention: SV001(drug)
Enrollment: 48 target
Eligibility: 40 years · All sexes
Timeline: 2025 – 2026

Study locations (12)

Sichuan Provincial People's Hospital, Chengdu, China
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China
Hangzhou First People's Hospital, Hangzhou, China
The First Affiliated Hospital of Nanchang University, Nanchang, China
Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China
The Affiliated Hospital of Inner Mongolia Medical University, Neimeng, China
Dongfang Hospital Affiliated to Tongji University, Shanghai, China
Huadong Hospital Affiliated to Fudan University, Shanghai, China
Shanghai Pulmonary Hospital, Shanghai, China
General Hospital of Tianjin Medical University, Tianjin, China
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China
Henan Provincial People's Hospital, Zhengzhou, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07121413 on ClinicalTrials.gov

Other trials for Idiopathic pulmonary fibrosis

Additional recruiting or active studies for the same condition.

See all trials for Idiopathic pulmonary fibrosis →

← Back to all trials